Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · October 15, 2020

Efficacy of Neratinib in HER2-Positive, HR-Positive Early-Stage Breast Cancer

Clinical Breast Cancer


Additional Info

Disclosure statements are available on the authors' profiles:

Clinical Breast Cancer
Final Efficacy Results of Neratinib in HER2-Positive Hormone Receptor-Positive Early Stage Breast Cancer From the Phase III ExteNET Trial
Clin. Breast Cancer 2020 Oct 06;[EPub Ahead of Print], A Chan, B Moy, J Mansi, et al

Further Reading